CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds ...

(RTTNews) - Akebia Therapeutics (AKBA), a biopharmaceutical company focused on kidney disease, Thursday has priced its underwritten public offering of 25 million common stock shares at $2.00 per ...